After grabbing 11702.0 shares, the institutional investor is now in possession of 11702.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.09% having worth around $5395.0. Moreover, UBS Securities LLC increased its share by 9665.0 to have a control over 9665.0 shares.
NeuroSense Therapeutics Ltd (NRSN) concluded trading on 12/14/23 at a closing price of $0.87, with 4.29 million shares of worth about $3.73 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -52.72% during that period and on Thursday the price saw a gain of about 27.93%. Currently the company’s common shares owned by public are about 11.78M shares, out of which, 9.09M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the stock later moved at a day high price of 0.9300, or with a gain of 27.93%. Stock saw a price change of 9.28% in past 5 days and over the past one month there was a price change of 77.53%. Year-to-date (YTD), NRSN shares are showing a performance of -28.70% which decreased to -44.59% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.40 but also hit the highest price of $2.91 during that period. The average intraday trading volume for NeuroSense Therapeutics Ltd shares is 786.75K. The stock is currently trading 8.16% above its 20-day simple moving average (SMA20), while that difference is up 37.07% for SMA50 and it goes to -29.69% lower than SMA200.
Citadel Securities LLC acquired 11702.0 shares of NeuroSense Therapeutics Ltd having value of about $5395.0. NeuroSense Therapeutics Ltd (NASDAQ: NRSN) currently have 11.78M outstanding shares and institutions hold larger chunk of about 5.72% of that. Holding of mutual funds in the company is about — while other institutional holders and individual stake holders have control over — and — of the stake respectively.
The stock has a current market capitalization of $11.85M and its 3Y-monthly beta is at 1.40. It has posted earnings per share of -$0.92 in the same period. It has Quick Ratio of 1.82. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NRSN, volatility over the week remained 14.46% while standing at 18.71% over the month.
Analysts are in expectations that NeuroSense Therapeutics Ltd (NRSN) stock would likely to be making an EPS of -$0.2 in the current quarter, while forecast for next quarter EPS is -$0.19 and it is -$0.8 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.2 which is -$0.2 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.24 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 23.36% while it is estimated to decrease by -0.61% in next year.
